Abbisko Cayman Valuation

Is 2256 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2256 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2256 (HK$3.12) is trading below our estimate of fair value (HK$4.76)

Significantly Below Fair Value: 2256 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2256?

Other financial metrics that can be useful for relative valuation.

2256 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does 2256's PB Ratio compare to its peers?

The above table shows the PB ratio for 2256 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.8x
2181 Mabpharm
6.8xn/aHK$1.5b
2315 Biocytogen Pharmaceuticals (Beijing)
3.5x100.1%HK$3.0b
2511 HighTide Therapeutics
2.4xn/aHK$1.8b
2105 Laekna
2.6xn/aHK$2.2b
2256 Abbisko Cayman
0.9x-26.5%HK$2.0b

Price-To-Book vs Peers: 2256 is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (3.8x).


Price to Earnings Ratio vs Industry

How does 2256's PE Ratio compare vs other companies in the HK Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.7%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.7%
n/an/an/a
No more companies

Price-To-Book vs Industry: 2256 is good value based on its Price-To-Book Ratio (0.9x) compared to the Hong Kong Biotechs industry average (1.6x).


Price to Book Ratio vs Fair Ratio

What is 2256's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2256 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 2256's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2256 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$3.12
HK$8.69
+178.7%
59.9%HK$15.84HK$3.57n/a3
Jun ’25HK$3.17
HK$8.20
+158.6%
56.5%HK$15.93HK$3.59n/a4
May ’25HK$3.30
HK$8.20
+148.4%
56.5%HK$15.93HK$3.59n/a4
Apr ’25HK$2.88
HK$8.20
+184.6%
56.5%HK$15.93HK$3.59n/a4
Mar ’25HK$2.66
HK$7.84
+194.6%
54.0%HK$15.99HK$3.65n/a5
Feb ’25HK$2.34
HK$7.89
+237.1%
54.7%HK$16.22HK$3.66n/a5
Jan ’25HK$3.65
HK$7.89
+116.1%
54.7%HK$16.22HK$3.66n/a5
Dec ’24HK$4.26
HK$7.34
+72.3%
64.4%HK$16.34HK$3.26n/a5
Nov ’24HK$2.90
HK$7.33
+152.7%
70.9%HK$16.05HK$3.20n/a4
Oct ’24HK$2.67
HK$7.33
+174.5%
70.9%HK$16.05HK$3.20n/a4
Sep ’24HK$2.38
HK$7.86
+230.3%
61.5%HK$16.04HK$3.54n/a4
Aug ’24HK$2.82
HK$6.85
+142.9%
64.4%HK$15.36HK$3.35n/a5
Jul ’24HK$2.68
HK$7.62
+184.4%
63.4%HK$15.83HK$3.32n/a4
Jun ’24HK$2.74
HK$7.62
+178.1%
63.4%HK$15.83HK$3.32HK$3.174
May ’24HK$2.95
HK$7.67
+160.1%
64.1%HK$16.03HK$3.36HK$3.304
Apr ’24HK$2.95
HK$7.67
+160.1%
64.1%HK$16.03HK$3.36HK$2.884
Mar ’24HK$3.06
HK$8.75
+185.8%
57.6%HK$15.92HK$3.14HK$2.665
Feb ’24HK$3.36
HK$9.10
+170.8%
58.3%HK$16.90HK$3.20HK$2.345
Jan ’24HK$3.21
HK$10.07
+213.7%
38.4%HK$15.87HK$5.59HK$3.655
Dec ’23HK$3.72
HK$10.07
+170.7%
38.4%HK$15.87HK$5.59HK$4.265
Nov ’23HK$2.85
HK$9.02
+216.6%
34.4%HK$12.93HK$5.01HK$2.905
Oct ’23HK$3.11
HK$8.90
+186.3%
35.9%HK$13.52HK$5.24HK$2.676
Sep ’23HK$4.00
HK$8.93
+123.4%
36.3%HK$13.62HK$5.28HK$2.386
Aug ’23HK$4.10
HK$7.94
+93.6%
30.7%HK$12.27HK$5.37HK$2.825
Jul ’23HK$3.58
HK$7.88
+120.1%
31.0%HK$12.36HK$5.32HK$2.685
Jun ’23HK$4.00
HK$10.00
+149.9%
44.9%HK$17.60HK$5.30HK$2.745

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.